您好,欢迎来到试剂仪器网! [登录] [免费注册]
试剂仪器网
位置:首页 > 产品库 > LHW090-A7
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
LHW090-A7
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
LHW090-A7图片
包装与价格:
包装价格(元)
5mg电议
10mg电议
25mg电议

产品介绍

化学性质

Physical AppearanceA crystalline solid
StorageStore at -20°C
M.Wt397.8
FormulaC20H21ClNO4·Na
Solubility≤1mg/ml in DMSO;5mg/ml in dimethyl formamide
Chemical Name(αS)-3'-chloro-α-[[(1S)-2-ethoxy-1-methyl-2-oxoethyl]amino]-[1,1'-biphenyl]-4-propanoic acid, monosodium salt
Canonical SMILESClC1=CC=CC(C2=CC=C(C[C@H](N[C@H](C(OCC)=O)C)C([O-])=O)C=C2)=C1.[Na+]
运输条件蓝冰运输或根据您的需求运输。
一般建议为了使其更好的溶解,请用37℃加热试管并在超声波水浴中震动片刻。不同厂家不同批次产品溶解度各有差异,仅做参考。若实验所需浓度过大至产品溶解极限,请添加助溶剂助溶或自行调整浓度。溶液形式一般不宜长期储存,请尽快用完。

资料参考

LHW090-A7 is a potential inhibitor of neutral endopeptidase (NEP). It has been shown that the NEP inhibitors induced the increase of plasma levels of endogenous atrial natriuretic peptides (NPs), which makes the inhibition of NEP to be a potential novel therapeutic approach.

NPs block the activity of the renin-angiotensin-aldosterone system, have antihypertrophic and antiproliferative effects, and reduce sympathetic drive. Additionally, NEP inhibitors are expected to trigger natriuretic and diuretic effects. NEP, a zinc-dependent, membrane-bound endopeptidase, hydrolyses peptides on the amino side of hydrophobic residues. It is essential for the processing and catabolism of vasoactive peptides as well as peptides involved in natriuresis and diuresis. NEP is indirectly and directly involved in the regulation of signaling pathways. NEP is implicated in proteolytic degradation or activation of bioactive peptides, growth factors, and cytokines in an indirect fashion. In addition to this, NEP is involved in regulating signaling pathways in a direct manner [1].

In vitro: Up to now, in vitro study of LHW090-A7 is still in the development stage.

In vivo: Up to now, in vivo study of LHW090-A7 is still in the development stage.

Reference:
[1].  Mangiafico, S., Costello-Boerrigter, L., Andersen, I., Cataliotti, A., & Burnett, J. Neutral endopeptidase inhibition and the natriuretic peptide system: an evolving strategy in cardiovascular therapeutics. European Heart Journal. 2012;34(12): 886-893.